CEbiotech.com - Central European Biotechnology Portal
be visible on the BioBusiness market                  ISSN 2300-0228
Most popular
searches

All articles

Filters:
Show search box
2015-02-17
Pierre Fabre initiates Phase IIa trials for a new drug for Schizophrenia

Pierre Fabre initiates Phase IIa trials for a new drug for Schizophrenia

A French multinational company Pierre Fabre Pharmaceuticals has announced a start of Phase IIa clinical trials for a new selective antagonist of dopamine D3 receptor called F17464 in patients suffering from schizophrenia. The major aim is to determine the effectiveness and assess safety of the drug d... Read more
Tags clinical trials , drug , Pierre Fabre , schizophrenia , F17464